This HTML5 document contains 162 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34269828
rdf:type
wikibase:Item
schema:description
2012年论文 2012 nî lūn-bûn bài báo khoa học מאמר מדעי article scientifique (publié 2012) artículu científicu espublizáu en 2012 wissenschaftlicher Artikel 2012年论文 სამეცნიერო სტატია 2012年論文 наукова стаття, опублікована у квітні 2012 ശാസ്ത്രപ്രബന്ധം​ 2012年论文 vedecký článok научна статия научни чланак vitskapeleg artikkel artículo científico publicado en 2012 articolo scientifico 2012年論文 artigo científico 2012년 논문 bilimsel makale 2012年の論文 2012年论文 мақолаи илмӣ artigo científico (publicado na 2012) مقالهٔ علمی научни чланак επιστημονικό άρθρο artykuł naukowy mokslinis straipsnis artikull shkencor 2012 թվականի ապրիլին հրատարակված գիտական հոդված vitenskapelig artikkel article científic wetenschappelijk artikel 2012年論文 article scientific scientific article 2012年论文 naučni članak vědecký článek научная статья 2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած vetenskaplig artikel سائنسی مضمون 2012年論文 мақолаи илмӣ 2012年论文 teaduslik artikkel tieteellinen artikkeli artigo científico (publicado na 2012) บทความทางวิทยาศาสตร์ videnskabelig artikel (udgivet 2012) artikulong pang-agham scienca artikolo tudományos cikk articol științific مقالة علمية ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2012年論文
p:P577
wds:Q34269828-D2A04E28-00B6-4277-8CA1-E28CE07286D4
wdt:P577
2012-04-01T00:00:00Z
p:P407
wds:Q34269828-6D2FD88C-8C15-4E10-8EB3-F4DEF17EDD44
wdt:P407
wd:Q1860
p:P2860
wds:Q34269828-5A35E2F3-4CFB-490A-8FFA-A79E2F7A61FB wds:Q34269828-4280DE0A-4550-4C39-BD55-E9821B6545FA wds:Q34269828-471AAC8E-FBC4-49C3-8861-8FC51043429F wds:Q34269828-08EADFEF-BF9A-4BEC-B051-BF3B9CE8C2EE wds:Q34269828-1D2E3C35-740B-447E-A58B-16F985176244 wds:Q34269828-209F95A6-12A8-4C9D-96A2-CEDBA6EDE5EE wds:Q34269828-DE65222D-FF70-4A65-987F-281AB1E438C5 wds:Q34269828-DEE55746-48AF-45C7-9097-461CDD6D66F4 wds:Q34269828-E6406F22-B14D-43B6-996A-D7CD331E2A79 wds:Q34269828-C77D8CE6-A897-4F09-B4F7-320069F71E85 wds:Q34269828-BDA29497-6445-4BB2-8214-1620094B2932 wds:Q34269828-C6F8FD03-683E-4100-8DD5-A40280E53893 wds:Q34269828-9A8D99EF-9DC6-4D3A-8D19-71F8E41BC7CF wds:Q34269828-A2BCB881-F749-42DB-98DF-7E7FE401291F wds:Q34269828-A720B2F0-A157-4DC3-B672-4B72F678D334 wds:Q34269828-90D803E9-6B54-4430-8015-8314FAEE1FCF wds:Q34269828-6ED73121-98D8-46EC-8B81-42C67A43C690 wds:Q34269828-7C02A0C0-657A-49BD-801F-F5C727AA41AA
wdt:P2860
wd:Q57412996 wd:Q42599961 wd:Q48288552 wd:Q72874429 wd:Q34425055 wd:Q37035202 wd:Q34583341 wd:Q37235951 wd:Q24642503 wd:Q44381371 wd:Q80336069 wd:Q36898852 wd:Q22250887 wd:Q78014804 wd:Q27861088 wd:Q37888699 wd:Q48491266 wd:Q81294679
p:P2093
wds:Q34269828-D054DDFC-4801-44B3-8504-1D83FE2CA1C6 wds:Q34269828-674A434F-6357-420E-9780-2897E284E092 wds:Q34269828-3001D2F8-4177-4D9C-80FC-50E57E20591D wds:Q34269828-36D4738F-75E1-4362-A9F1-21BAAE1C3F36 wds:Q34269828-B782D64F-0634-4604-9CA9-6B4E9591792F wds:Q34269828-7115A8FA-7B4A-4B1D-9D5A-4D316F844443 wds:Q34269828-8733B5E4-6062-41C2-954F-EEBDDB4FC55B
wdt:P2093
Huiling Pei Miles Fisher Eric Renard David Russell-Jones BEGIN Basal-Bolus Type 1 Trial Investigators Bruce Bode Ludwig Merker
rdfs:label
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria
skos:prefLabel
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria
schema:name
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria
p:P50
wds:Q34269828-057627CE-5A15-4DAE-B923-1F2CCE5160EF wds:Q34269828-2EC8A7D9-85B9-4ED3-9F51-5FA04B2D6159 wds:Q34269828-3F5E6455-92FA-4586-A434-CBBCEA2D014B wds:Q34269828-504CF2B0-9709-4FF4-B694-462380D584DF wds:Q34269828-6D839464-9A55-4D02-B3DD-64D22CAFF157 wds:Q34269828-976D35CB-7D8A-495E-80FF-C5D98347A333
wdt:P50
wd:Q6224073 wd:Q114738154 wd:Q38550003 wd:Q125329533 wd:Q37631006 wd:Q125330192
p:P1476
wds:Q34269828-D3EFA80C-952E-4C1C-8D83-EC200233D0F8
wdt:P1476
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria
p:P304
wds:Q34269828-4AE98A14-3A83-4683-A0D7-5AA26AC382A5
wdt:P304
1489-1497
p:P31
wds:Q34269828-98D70260-0B76-4BCA-8C32-341E8F96FD55
wdt:P31
wd:Q13442814
p:P921
wds:Q34269828-EA570CC3-655F-43A1-B01A-C5B1086EC548 wds:Q34269828-9C209CE1-B6AA-44F2-B83F-B98CAA819258 wds:Q34269828-07E33842-10D0-4379-88C8-42868754B06D
wdt:P921
wd:Q124407 wd:Q7240673 wd:Q417317
p:P698
wds:Q34269828-BE164442-AA12-4489-BBDB-1AE496B94502
wdtn:P698
n12:22521071
wdt:P698
22521071
p:P1433
wds:Q34269828-456ABF5C-AFBD-49B7-9694-9A270C481F0A
wdt:P1433
wd:Q939416
p:P433
wds:Q34269828-EF2A0E5C-3438-4A97-BF55-D902ABE31C64
p:P478
wds:Q34269828-3F960BC9-DACB-442F-BD82-46B946A019F0
wdt:P433
9825
wdt:P478
379
p:P356
wds:Q34269828-FCABD93E-1D8A-485A-B968-274F07BAE4FA
wdtn:P356
n11:S0140-6736(12)60204-9
wdt:P356
10.1016/S0140-6736(12)60204-9